Current Perspectives in Kidney Diseases. Группа авторов
Recent data on RCA in patients with liver failure undergoing CRRT have provided important information. In spite of substantial increases in citrate levels, the metabolic consequences were less significant than expected: a trend towards metabolic alkalosis was found instead of acidosis, and no significant electrolyte disturbances (including hypocalcemia) were observed [26]. Blood citrate levels were related to the calcium ratio; prothrombin activity <26% and lactate level >3.4 mmol/L proved to be acceptable predictors of citrate accumulation. However, a more recent retrospective study suggested that we may further restrict the exclusion criteria for RCA, describing the association between the incidence of citrate accumulation and more elevated lactate levels (>7.5 mmol/L) [23]. Most of these issues can be deemed valid in the case of extracorporeal liver support treatments usually adopted as a “bridge” to liver transplantation or liver recovery, such as the Molecular Adsorbent Recirculating System and Prometheus System. In our experience with Prometheus, RCA was a safe and effective anticoagulation modality [27, 29, 30].
Conclusion
The use of citrate represents a valid alternative to traditional anticoagulation with heparin during CRRT since it reduces the bleeding risk and increases the efficiency of the treatment. The increase of filter life span in fact, is not a goal to be pursued in itself, but the reduction of the filter clotting events within the first 48–72 h reduces the discrepancy between the prescribed and delivered dialysis doses. With recent technological innovations, the RCT during CRRT can be conducted safely with minimal risk of complications even in patients at the highest risk of citrate accumulation such as patients with liver dysfunction.
References
1 Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004;50:76–80.
2 Joannidis M, Oudemans-van Straaten HM: Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007;11:218.
3 Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A: Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int 2001;59:1510–1519.
4 Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E: Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol 2014;9:2173–2188.
5 van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC: Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145–150.
6 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2012;2(suppl):1–138.
7 Mariano F, Morselli M, Bergamo D, Hollo Z, Scella S, Maio M, Tetta C, Dellavalle A, Stella M, Triolo G: Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant 2011;26:3882–3888.
8 Davenport A, Tolwani A: Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus 2009;2:439–447.
9 Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW: Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012;59:810–818.
10 Liu C, Mao Z, Kang H, Hu J, Zhou F: Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care 2016;20:144.
11 Betjes MG, van Oosterom D, van Agteren M, van de Wetering J: Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007;20:602–608.
12 Morabito S, Pistolesi V, Tritapepe L, Zeppilli L, Polistena F, Strampelli E, Pierucci A: Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012;16:R111.
13 Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545–552.
14 Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011;26:232–239.
15 Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R: Randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med 2015;43:1622–1629.
16 Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004;30:260–265.
17 Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005;67:2361–2367.
18 Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, Vervloet MG, Beishuizen A, Girbes AR, Ter Wee PM, Groeneveld AB; CASH Study Group: Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014;18:472.
19 Stucker F, Ponte B, Tataw J, Martin PY, Wozniak H, Pugin J, Saudan P: Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015;19:91.